To include your compound in the COVID-19 Resource Center, submit it here.

Adolor chronicles

Adolor chronicles

After hitting a six-year high last September, Adolor (ADLR) began a steady descent when it and partner GlaxoSmithKline (LSE:GSK; GSK) reported mixed Phase III data on their Entereg bowel dysfunction candidate. ADLR took another hit in November when it received a second approvable letter for Entereg asking for 12-month safety data. Those data came out

Read the full 564 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE